Efficacy Analysis of Different Doses of Lenalidomide in the Treatment of Newly Diagnosed Advanced Multiple Myeloma
Objective To analyze the application value of different doses of lenalidomide in patients with newly diagnosed advanced multiple myeloma(MM).Methods A total of 84 patients with newly diagnosed advanced multiple myeloma treated at Sanmenxia Central Hospital from January 2021 to January 2023 were selected for the study.All patients received PRD(bortezomib 1.3 mg/m2/d,lenalidomide and dexamethasone 20 mg/d)chemotherapy.They were randomly divided into a control group and a study group,each comprising 42 patients.The control group received lenalidomide at a dose of 25 mg/day,while the study group received lenalidomide at a dose of 10 mg/day.The treatment efficacy after two cycles,patient survival rates,clinical indicators,and the incidence of drug side effects were compared between both groups.Results The efficacy rate in the study group was lower than that in the control group,but the difference was not statistically significant(P＞0.05).The one-year progression-free survival(PFS)rate and one-year overall survival(OS)rate in the study group were both higher than those in the control group,but the differences were not statistically significant(P＞0.05).The decrease rate of globulin in the study group was higher than that in the control group,while the decrease rates of β2-microglobulin(β2-MG),the rate of negative immunofixation electrophoresis,and the rate of negative Bence Jones protein in urine were all lower than those in the control group,with no significant differences between the groups(P＞0.05).However,the incidence of drug side effects(leukopenia,thrombocytopenia,peripheral neuropathy)in the study group was lower than that in the control group,with a statistically significant difference(P＜0.05).Conclusion Low-dose lenalidomide treatment for MM has equivalent clinical efficacy to conventional dosing but can reduce the incidence of drug side effects.This approach provides considerable safety and high application value while effectively regulating immune function and prolonging survival.
different dosesLenalidomidemultiple myelomaclinical efficacysurvivaldrug side effects
国家科技期刊平台
NSTL
万方数据
